Compare McKesson Corporation (MCK) vs Taskus Inc (TASK) Price & Performance

McKesson Corporation (MCK) trades at $930.25, up 2.19% with strong technical momentum and bullish analyst sentiment. The stock shows consistent earnings beats with Q2 2026 EPS of $9.93 exceeding expectations of $9.56. Recent news highlights the extension of McKesson's pharmaceutical distribution agreement with CVS Health through 2032, reinforcing long-term revenue visibility. Revenue growth remains robust, climbing from $264.0B in 2022 to $359.1B in 2025, though net margins are thin at 1.12%.

McKesson presents a favorable risk-reward profile with 81% analyst buy ratings and a $956.43 consensus price target offering 2.8% upside. Key risks include margin pressure from drug pricing dynamics and policy uncertainty. The company's strong cash flow generation ($6.1B operating cash flow in 2025) and strategic focus on oncology and specialty distribution support continued growth, though investors should monitor debt levels and competitive pressures in healthcare distribution.

TaskUs (TASK) trades at $8.01, up 1.52% today, with a bearish technical signal but strong fundamentals. The company reported Q2 2026 revenue of $308.9 million, beating estimates, with net income margin improving to 8.75% in 2025. Valuation ratios appear attractive, with a P/E of 6.8 and P/S of 0.6, while analyst consensus is a Buy with a $9.33 price target. Recent news highlights AI services growth offsetting declines in other segments.

The outlook is mixed; low valuations and AI-driven revenue growth present upside, but technical bearishness and margin pressures from labor costs pose risks. Investors should weigh fundamental strength against near-term price volatility and competitive challenges in the digital services space.